Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Passage Bio

Passage Bio
Regional

Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia

June 24, 2025June 23, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia (FTD) …

Passage Bio Reports Progress in Gene Therapy for Frontotemporal Dementia Read More

Passage Bio
Regional

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025May 16, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared its financial results for the first quarter of 2025, along with updates on its ongoing clinical programs and operational advancements. …

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development Read More
Passage Bio
Regional

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program

March 5, 2025March 4, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced its 2024 financial results, highlighting progress in its PBFT02 gene therapy program for frontotemporal dementia (FTD) associated with GRN mutations (FTD-GRN) …

Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program Read More

Passage Bio
Regional

Passage Bio to Present at Two Major Investor Conferences

February 27, 2025February 26, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced its participation in two upcoming investor conferences, where management will share updates on the company’s progress and engage with stakeholders.

Passage Bio to Present at Two Major Investor Conferences Read More
Passage Bio
Regional

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment

January 11, 2025January 10, 2025 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More

Passage Bio
Regional

Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results

November 14, 2024November 13, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …

Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More
Passage Bio
Regional

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia

September 18, 2024September 17, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. has unveiled promising interim data from its ongoing global Phase 1/2 upliFT-D clinical trial at the 14th International Conference on Frontotemporal Dementias (ISFTD2024). The study …

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia Read More

Passage Bio
Regional

Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision

September 11, 2024September 10, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has announced the appointment of Tom Kassberg to its Board of Directors, along with his role on the Audit Committee, marking a significant …

Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision Read More
Passage Bio
Regional

Passage Bio Reports Q2 2024 Financial Results and Business Updates

August 10, 2024August 9, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) released its financial results for the second quarter ended June 30, 2024, along with significant business highlights.

Passage Bio Reports Q2 2024 Financial Results and Business Updates Read More
Passage Bio
Regional

Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics

August 2, 2024August 2, 2024 - by Timothy Alexander

PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced a series of agreements to out-license its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. (GEMMABio). The …

Passage Bio Out-Licenses Rare Disease Programs to GEMMA Biotherapeutics Read More

Posts pagination

1 2 Next

Trending News

  • Tower of Power to Bring Legendary Funk and Soul to Rivers Casino Philadelphia on August 1

  • Ginuwine to Bring Iconic R&B Hits to Rivers Casino Philadelphia on August 2

  • Get Ready, Chester County: Sunshine, Soakers, and Sizzle — Your Wild Week of Weather Awaits!

  • Trinseo Reports Major Emissions Reduction and Advances in Circular Economy in 2024 Sustainability Report

  • AARP Warns Pennsylvania Seniors of Rising Utility Scams Amid Surge in Fraud Reports

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Scam Alert

AARP Warns Pennsylvania Seniors of Rising Utility Scams Amid Surge in Fraud Reports

July 5, 2025July 4, 2025

Ketamine hydrochloride

Philadelphia CBP Officers Seize $1.5 Million in Ketamine Shipments

July 5, 2025July 4, 2025

Arrest

Seven Charged in Blair County Drug-Trafficking Bust; Supplier Accused in 2022 Overdose Death

July 4, 2025July 4, 2025

Copyright © 2025 MyChesCo.